Rofecoxib inhibits heterotopic ossification after total hip arthroplasty


    loading  Checking for direct PDF access through Ovid

Abstract

IntroductionNonsteroidal anti-inflammatory drugs (NSAIDs) prevent heterotopic ossification but gastrointestinal complaints are frequently. Selective cyclooxygenase-2 (COX-2) inhibiting NSAID produce less gastrointestinal side effects.Patients and methodsA prospective two-stage study design for phase 2 clinical trials with 42 patients was used to determine if rofecoxib (a COX-2 inhibitor) 50 mg oral for 7 days prevents heterotopic ossification. A cemented primary THA was inserted for osteoarthroses. After 6 months heterotopic bone formation was assessed on AP radiographs using the Brooker classification.ResultsNo heterotopic ossification was found in 81% of the patients, 19% of the patients had Brooker grade 1 ossification.ConclusionUsing a two-stage study design for phase 2 clinical trials, a 7-day treatment of a COX-2 inhibitor (rofecoxib) prevents effectively the formation of heterotopic ossification after cemented primary total hip arthroplasty.

    loading  Loading Related Articles